Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer - Trial NCT06411678
Access comprehensive clinical trial information for NCT06411678 through Pure Global AI's free database. This Phase 1 trial is sponsored by Peking Union Medical College Hospital and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
Phase 1
May 10, 2024
Jun 01, 2026
Primary Outcome
The evaluation of diagnostic performance of 68Ga-DOTA-dPNE PET in breast cancer
Summary
We plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study on breast cancer patients to observe
 the binding of the tracer to lesions and evaluate CD73 expression. Alongside this, we will
 correlate these imaging results with relevant clinical indicators to assess the effectiveness
 of 68Ga-DOTA-dPNE in diagnosing and guiding treatment in breast cancer patients. This study
 aims to predict responses to targeted therapies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411678
Non-Device Trial